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Is the Implantable Defibrillator
Indicated in Patients With
Hypertrophic Cardiomyopathy
and Aborted Sudden Death?*
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GU¨NTER BREITHARDT, MD, FACC, FESC
Mu¨nster, Germany
The natural history of patients with hypertrophic cardiomyop-
athy (HCM) is characterized by slow progression of symptoms
(i.e., angina or dyspnea, or both) and left ventricular hypertro-
phy. Severe functional limitation is unusual and is encountered
in only ;20% of patients. Approximately 50% of deaths are
sudden (1). Although complete heart block may complicate
myectomy, the development of symptomatic conduction dis-
ease in patients not undergoing operation is rare. Pre-
excitation syndromes may be present in a small proportion of
patients (2%) but appear to be seldom responsible for sudden
death in HCM. A short PR interval with a broad QRS complex
might mimic the presence of a Wolff-Parkinson-White syn-
drome in some patients with HCM. This finding may be
explained by an abnormal septal activation of the hypertro-
phied septum. We recently studied a cohort of 65 patients
(unpublished observations) with HCM and either documented
or suspected ventricular tachyarrhythmias undergoing invasive
electrophysiologic study. Surprisingly, in ;20% of patients,
enhanced atrioventricular (AV) node conduction was ob-
served, allowing 1:1 conduction with ventricular rates up to 280
beats/min in the absence of an accessory pathway. This finding
may be of clinical importance as a possible trigger mechanism
of sudden arrhythmic death in HCM because these high
ventricular rates during paroxysmal atrial fibrillation may be
detrimental in patients with HCM and impaired diastolic
filling. Outflow tract obstruction and coronary spasm have
been suggested as a causal factor. However, these mechanisms
have not yet been shown to be of importance. Further hypoth-
eses, currently also not proven, have implicated acute changes
in diastolic filling, acute myocardial ischemia or impaired
autonomic regulation as causes of sudden death. Currently, not
much information is available concerning the mechanism of
sudden death in HCM, making risk stratification difficult.
Presently, no convincing data are available for effective risk
stratification of patients with HCM (2–4). This inability to
correctly identify patients at risk of sudden cardiac death in
HCM reflects our poor understanding of the mechanisms of
sudden death in this entity. Although some initiating mecha-
nisms have been identified in single cases, such as atrial
fibrillation with rapid ventricular conduction, altered barore-
flex control of peripheral blood flow and others, the extent of
myocardial disarray and a potential for ischemic events in
patients with HCM have to be better characterized before
appropriate pharmacologic or nonpharmacologic interven-
tions, such as myectomy or implantation of an implantable
cardioverter-defibrillator (ICD), are undertaken.
The available data suggest that ventricular tachyarrhyth-
mias are the cause of sudden death in most patients with HCM,
either as a primary event related to an arrhythmogenic sub-
strate or as a secondary phenomenon triggered by myocardial
ischemia, diastolic dysfunction, outflow tract obstruction or
supraventricular tachyarrhythmias. Conventional risk factor
stratification, including family history, presence of syncope and
nonsustained ventricular tachycardia (VT) during Holter mon-
itoring, identifies a cohort of patients at increased risk for
sudden cardiac death. In ;30% of this group a probable
initiating mechanism that is amenable to specific therapy can
be identified. Treatment may be targeted at the prevention of
paroxysmal atrial fibrillation, which can be effectively pre-
vented with amiodarone; conduction disease by a cardiac
pacemaker; rapid AV conduction through an accessory path-
way by radiofrequency catheter ablation; ischemia with high
dose verapamil; and left ventricular outflow tract obstruction
by myectomy or dual-chamber pacing or, recently, by occlusion
of the septal branches of the left anterior descending coronary
artery. However, in the remaining group (;70%), the patient
is recognized as being at increased risk, but there are either
multiple potential triggers or nonidentifiable triggers that
can be targeted. There is general agreement that patients
with cardiac arrest and documented ventricular fibrillation,
who rarely survive this event, or patients with HCM and
episodes of sustained monomorphic VT, although rare in
HCM, represent the patient cohort at highest risk for
sudden death.
In the present issue of the Journal, Primo et al. (5) report
the results of a retrospective analysis of the occurrence of
cardiac events during follow-up in 13 patients with HCM who
received an ICD because of either aborted sudden death (n 5
10) or sustained ventricular tachycardia (n 5 3). The results
and findings were compared with those in 215 patients with an
ICD and other structural heart diseases or idiopathic ventric-
ular fibrillation. During the mean follow-up period of 26 6 18
months, only 2 of 13 patients with HCM received appropriate
shocks. The calculated cumulative incidence of shocks was
21% in the patients with HCM and 66% in the remaining
patients after 40 months. The patient cohort with HCM is
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poorly characterized concerning clinical characteristics and
echocardiographic findings as well as the circumstances of the
cardiac event before ICD implantation. Seven of 13 patients
received amiodarone before ICD implantation for unspecified
reasons. After ICD implantation, all but one patient received
either a beta-adrenergic blocking agent, verapamil or amioda-
rone, making assessment of the impact of ICD implantation on
prognosis impossible. The conclusion that the ICD seems to
have a less important impact on prognosis in patients with
HCM than in patients with other etiologies of aborted sudden
death is poorly substantiated by the authors. Additionally, the
report compares a small patient cohort with a large patient
group with different underlying cardiac etiologies. Given the
small patient numbers and the varying follow-up period in the
small group of patients with HCM, the authors should have
given standard deviations in the Kaplan-Meyer event curves to
illustrate that their observations were due to chance in a highly
selected group of patients with HCM.
Although the use of an ICD remains controversial in
patients with HCM, and there is a lack of information in the
published reports, three recent studies, presented only in part
at meetings, have addressed the outcome in patients with
HCM and an ICD. Silka et al. (6) reported on 44 patients with
HCM of a cohort of 177 young patients (,20 years old)
receiving an ICD. In the subgroup of 44 patients with HCM, 25
(57%) received appropriate ICD discharges during a mean
follow-up period of 31 6 23 months. A similar observation was
made by Tripodi et al. (7) who reported on 31 patients with an
ICD and HCM who were followed up over 33 6 7 months, with
a reported incidence of 32% appropriate discharges. At our
referral center, ,2% of ICD recipients were diagnosed as
having HCM. Fourteen patients received an ICD and were
followed up for 48 6 24 months; 43% of patients had an
appropriate ICD intervention during follow-up, as assessed by
third-generation devices with memory function.
Taking these observations into account in comparing the
low event rate in the present study by Primo et al. (8), one is
left with the impression that one is dealing with a highly
selected subgroup of patients in which additional pharmaco-
logic therapy may have had some impact on the low event rate
during follow-up. This controversy underlines the need for a
prospective trial in high risk patients with HCM and the need
for a registry to collect data on the outcome of patients
undergoing different therapeutic interventions, such as DDD
pacing, septal ablation, myectomy or ICD implantation, alone
or in combination.
Currently, in Europe there is a prospective registry on
HCM and ICD implantation on the way supported by the
Working Group on Arrhythmias and the Working Group on
Myocardial and Pericardial Diseases of the European Society
of Cardiology, which was initiated by Martin Borggrefe, Mu¨n-
ster, Germany and William McKenna, London, United King-
dom. Possibly, this registry will give some definite answer
concerning the role of ICD implantation in cardiac arrest
survivors and HCM. Whether other nonpharmacologic inter-
ventions, such as septal ablation, DDD pacing or myectomy,
have some impact on the management of sudden cardiac death
survivors remains speculative.
Recently, we prospectively studied 10 patients after cardiac
arrest who underwent myectomy for hypertrophic obstructive
cardiomyopathy (HOCM) (8). Eight of 10 patients had induc-
ible sustained ventricular tachycardia or fibrillation before
operation. After myectomy, only no to six ventricular re-
sponses were inducible in all 10 patients by means of a
stimulation protocol that included up to three extrastimuli. No
recurrent arrhythmic event occurred during a follow-up period
of 4.5 years in the absence of antiarrhythmic drugs. This
preliminary observation may be explained by surgical removal
of an “arrhythmogenic substrate” in some patients with
HOCM and life-threatening tachyarrhythmias and may sup-
port a potential mechanism for the beneficial long-term results
after surgical treatment. Therefore, in patients with cardiac
arrest and inducible ventricular tachyarrhythmias, myectomy
may be the treatment of choice and presents a curative
approach in contrast to implantation of an ICD.
Conclusions. The report by Primo et al. (5) initiates a new
discussion on the value of an ICD in patients with HCM and
aborted sudden cardiac death. At present, the patient with
sustained ventricular tachyarrhythmias and HCM should un-
dergo implantation of an ICD (9), unless there is a specific
trigger that can be effectively targeted or a potential ar-
rhythmogenic substrate that can be abolished effectively by
myectomy, especially in patients with HOCM or apical aneu-
rysms. The low peri-implant mortality and morbidity of the
transvenous lead systems make ICD implantation a logical and
cost-effective form of therapy. The availability of improved
logging of arrhythmic events and the rhythm immediately
preceding arrhythmia detection may provide new information
in this group that in future will help to decide with more
security which patient should undergo ICD implantation.
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Abbreviations and Acronyms
AV 5 atrioventricular
HCM 5 hypertrophic cardiomyopathy
HOCM 5 hypertrophic obstructive cardiomyopathy
ICD 5 implantable cardioverter-defibrillator
VT 5 ventricular tachycardia
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